A citation-based method for searching scientific literature

Enli Liu, David Marin, Pinaki Banerjee, Homer A Macapinlac, Philip Thompson, Rafet Basar, Lucila Nassif Kerbauy, Bethany Overman, Peter Thall, Mecit Kaplan, Vandana Nandivada, Indresh Kaur, Ana Nunez Cortes, Kai Cao, May Daher, Chitra Hosing, Evan N Cohen, Partow Kebriaei, Rohtesh Mehta, Sattva Neelapu, Yago Nieto, Michael Wang, William Wierda, Michael Keating, Richard Champlin, Elizabeth J Shpall, Katayoun Rezvani. N Engl J Med 2020
Times Cited: 630







List of co-cited articles
1346 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
E Liu, Y Tong, G Dotti, H Shaim, B Savoldo, M Mukherjee, J Orange, X Wan, X Lu, A Reynolds,[...]. Leukemia 2018
308
26

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Shannon L Maude, Theodore W Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R Verneris, Heather E Stefanski, Gary D Myers,[...]. N Engl J Med 2018
24

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.
Ye Li, David L Hermanson, Branden S Moriarity, Dan S Kaufman. Cell Stem Cell 2018
354
20

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.
Jeffrey S Miller, Yvette Soignier, Angela Panoskaltsis-Mortari, Sarah A McNearney, Gong H Yun, Susan K Fautsch, David McKenna, Chap Le, Todd E Defor, Linda J Burns,[...]. Blood 2005
20

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
19

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.
Rizwan Romee, Maximillian Rosario, Melissa M Berrien-Elliott, Julia A Wagner, Brea A Jewell, Timothy Schappe, Jeffrey W Leong, Sara Abdel-Latif, Stephanie E Schneider, Sarah Willey,[...]. Sci Transl Med 2016
396
19

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
Loredana Ruggeri, Marusca Capanni, Elena Urbani, Katia Perruccio, Warren D Shlomchik, Antonella Tosti, Sabrina Posati, Daniela Rogaia, Francesco Frassoni, Franco Aversa,[...]. Science 2002
17

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
17

NK cells for cancer immunotherapy.
Noriko Shimasaki, Amit Jain, Dario Campana. Nat Rev Drug Discov 2020
274
17


Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew A Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G Maloney, Charalambos Andreadis,[...]. Lancet 2020
391
15

CAR-NK cells: A promising cellular immunotherapy for cancer.
Guozhu Xie, Han Dong, Yong Liang, James Dongjoo Ham, Romee Rizwan, Jianzhu Chen. EBioMedicine 2020
164
14

Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.
Cecele J Denman, Vladimir V Senyukov, Srinivas S Somanchi, Prasad V Phatarpekar, Lisa M Kopp, Jennifer L Johnson, Harjeet Singh, Lenka Hurton, Sourindra N Maiti, M Helen Huls,[...]. PLoS One 2012
333
14

Exploring the NK cell platform for cancer immunotherapy.
Jacob A Myers, Jeffrey S Miller. Nat Rev Clin Oncol 2021
156
14

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
Jae H Park, Isabelle Rivière, Mithat Gonen, Xiuyan Wang, Brigitte Sénéchal, Kevin J Curran, Craig Sauter, Yongzeng Wang, Bianca Santomasso, Elena Mead,[...]. N Engl J Med 2018
13

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.
Hiroyuki Fujisaki, Harumi Kakuda, Noriko Shimasaki, Chihaya Imai, Jing Ma, Timothy Lockey, Paul Eldridge, Wing H Leung, Dario Campana. Cancer Res 2009
388
13

Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.
May Daher, Rafet Basar, Elif Gokdemir, Natalia Baran, Nadima Uprety, Ana Karen Nunez Cortes, Mayela Mendt, Lucila Nassif Kerbauy, Pinaki P Banerjee, Mayra Shanley,[...]. Blood 2021
66
18

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman,[...]. Lancet Oncol 2019
807
11

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.
Margery Gang, Nancy D Marin, Pamela Wong, Carly C Neal, Lynne Marsala, Mark Foster, Timothy Schappe, Wei Meng, Jennifer Tran, Maximilian Schaettler,[...]. Blood 2020
52
21

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn,[...]. N Engl J Med 2020
447
11

Human chimeric antigen receptor macrophages for cancer immunotherapy.
Michael Klichinsky, Marco Ruella, Olga Shestova, Xueqing Maggie Lu, Andrew Best, Martha Zeeman, Maggie Schmierer, Konrad Gabrusiewicz, Nicholas R Anderson, Nicholas E Petty,[...]. Nat Biotechnol 2020
262
11

First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.
Xiaowen Tang, Lin Yang, Zheng Li, Ansel P Nalin, Haiping Dai, Ting Xu, Jia Yin, Fengtao You, Mingqing Zhu, Wenhong Shen,[...]. Am J Cancer Res 2018
172
10

Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
Lin Xiao, Dongzhi Cen, Haining Gan, Yan Sun, Nanqi Huang, Hanzhen Xiong, Qiongmei Jin, Liqun Su, Xuejuan Liu, Kejian Wang,[...]. Mol Ther 2019
76
13


Targeting natural killer cells in cancer immunotherapy.
Camille Guillerey, Nicholas D Huntington, Mark J Smyth. Nat Immunol 2016
580
10

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
Pascale André, Caroline Denis, Caroline Soulas, Clarisse Bourbon-Caillet, Julie Lopez, Thomas Arnoux, Mathieu Bléry, Cécile Bonnafous, Laurent Gauthier, Ariane Morel,[...]. Cell 2018
468
10

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
Daniel A Vallera, Martin Felices, Ron McElmurry, Valarie McCullar, Xianzheng Zhou, Joerg Uwe Schmohl, Bin Zhang, Alexander J Lenvik, Angela Panoskaltsis-Mortari, Michael R Verneris,[...]. Clin Cancer Res 2016
185
10

CIS is a potent checkpoint in NK cell-mediated tumor immunity.
Rebecca B Delconte, Tatiana B Kolesnik, Laura F Dagley, Jai Rautela, Wei Shi, Eva M Putz, Kimberley Stannard, Jian-Guo Zhang, Charis Teh, Matt Firth,[...]. Nat Immunol 2016
175
10

Cytokine activation induces human memory-like NK cells.
Rizwan Romee, Stephanie E Schneider, Jeffrey W Leong, Julie M Chase, Catherine R Keppel, Ryan P Sullivan, Megan A Cooper, Todd A Fehniger. Blood 2012
316
10

Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.
Stefan O Ciurea, Jolie R Schafer, Roland Bassett, Cecele J Denman, Kai Cao, Dana Willis, Gabriela Rondon, Julianne Chen, Doris Soebbing, Indreshpal Kaur,[...]. Blood 2017
159
10

Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity.
Huang Zhu, Robert H Blum, Davide Bernareggi, Eivind Heggernes Ask, Zhengming Wu, Hanna Julie Hoel, Zhipeng Meng, Chengsheng Wu, Kun-Liang Guan, Karl-Johan Malmberg,[...]. Cell Stem Cell 2020
64
15

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Daniel W Lee, James N Kochenderfer, Maryalice Stetler-Stevenson, Yongzhi K Cui, Cindy Delbrook, Steven A Feldman, Terry J Fry, Rimas Orentas, Marianna Sabatino, Nirali N Shah,[...]. Lancet 2015
9

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Marco L Davila, Isabelle Riviere, Xiuyan Wang, Shirley Bartido, Jae Park, Kevin Curran, Stephen S Chung, Jolanta Stefanski, Oriana Borquez-Ojeda, Malgorzata Olszewska,[...]. Sci Transl Med 2014
9

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.
Zeguo Zhao, Maud Condomines, Sjoukje J C van der Stegen, Fabiana Perna, Christopher C Kloss, Gertrude Gunset, Jason Plotkin, Michel Sadelain. Cancer Cell 2015
441
9

'Off-the-shelf' allogeneic CAR T cells: development and challenges.
S Depil, P Duchateau, S A Grupp, G Mufti, L Poirot. Nat Rev Drug Discov 2020
248
9

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
Jianfeng Han, Jianhong Chu, Wing Keung Chan, Jianying Zhang, Youwei Wang, Justus B Cohen, Aaron Victor, Walter H Meisen, Sung-Hak Kim, Paola Grandi,[...]. Sci Rep 2015
190
9

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.
Rizwan Romee, Sarah Cooley, Melissa M Berrien-Elliott, Peter Westervelt, Michael R Verneris, John E Wagner, Daniel J Weisdorf, Bruce R Blazar, Celalettin Ustun, Todd E DeFor,[...]. Blood 2018
190
9

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Nikhil C Munshi, Larry D Anderson, Nina Shah, Deepu Madduri, Jesús Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, David Siegel, Albert Oriol,[...]. N Engl J Med 2021
266
9

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
Jordan Gauthier, Alexandre V Hirayama, Janaki Purushe, Kevin A Hay, James Lymp, Daniel H Li, Cecilia C S Yeung, Alyssa Sheih, Barbara S Pender, Reed M Hawkins,[...]. Blood 2020
118
9

Are natural killer cells superior CAR drivers?
Hans Klingemann. Oncoimmunology 2014
147
9

The Broad Spectrum of Human Natural Killer Cell Diversity.
Aharon G Freud, Bethany L Mundy-Bosse, Jianhua Yu, Michael A Caligiuri. Immunity 2017
290
9

CRISPR-engineered T cells in patients with refractory cancer.
Edward A Stadtmauer, Joseph A Fraietta, Megan M Davis, Adam D Cohen, Kristy L Weber, Eric Lancaster, Patricia A Mangan, Irina Kulikovskaya, Minnal Gupta, Fang Chen,[...]. Science 2020
450
9

Cytokine-induced memory-like natural killer cells.
Megan A Cooper, Julie M Elliott, Peter A Keyel, Liping Yang, Javier A Carrero, Wayne M Yokoyama. Proc Natl Acad Sci U S A 2009
474
9

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.
Emily J Pomeroy, John T Hunzeker, Mitchell G Kluesner, Walker S Lahr, Branden A Smeester, Margaret R Crosby, Cara-Lin Lonetree, Kenta Yamamoto, Laura Bendzick, Jeffrey S Miller,[...]. Mol Ther 2020
56
14

Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L Maude, Noelle Frey, Pamela A Shaw, Richard Aplenc, David M Barrett, Nancy J Bunin, Anne Chew, Vanessa E Gonzalez, Zhaohui Zheng, Simon F Lacey,[...]. N Engl J Med 2014
8

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Stephen J Schuster, Jakub Svoboda, Elise A Chong, Sunita D Nasta, Anthony R Mato, Özlem Anak, Jennifer L Brogdon, Iulian Pruteanu-Malinici, Vijay Bhoj, Daniel Landsburg,[...]. N Engl J Med 2017
903
8

Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.
Hua Jiang, Wenhao Zhang, Peipei Shang, Hui Zhang, Weijun Fu, Fei Ye, Tianmei Zeng, Hejing Huang, Xueguang Zhang, Wanping Sun,[...]. Mol Oncol 2014
157
8

Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Nadja Müller, Susanne Michen, Stefanie Tietze, Katrin Töpfer, Alexander Schulte, Katrin Lamszus, Marc Schmitz, Gabriele Schackert, Ira Pastan, Achim Temme. J Immunother 2015
115
8

Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.
C Quintarelli, S Sivori, S Caruso, S Carlomagno, M Falco, I Boffa, D Orlando, M Guercio, Z Abbaszadeh, M Sinibaldi,[...]. Leukemia 2020
41
19

DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
Katrin Töpfer, Marc Cartellieri, Susanne Michen, Ralf Wiedemuth, Nadja Müller, Dirk Lindemann, Michael Bachmann, Monika Füssel, Gabriele Schackert, Achim Temme. J Immunol 2015
117
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.